FDA approves the third NMOSD drug in 18 months as Roche/Genentech beefs up its portfolio of drugs for neurological disorders
There were no FDA approved treatments for neuromyelitis optica spectrum disorder at the start of 2019. Now, as of Friday, there are three.
The latest …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
